⏱ 17 min read
Hospital 366 Days · Case No. 16
The hospital’s year does not end at 365. It runs to 366, and keeps going.
Call her Ruth. Age, occupation, location, and any potentially identifying details have been changed. The clinical pattern is a composite reconstructed from cases that American emergency rooms see repeatedly over a year, and it does not represent any specific patient.
Heart failure rising BNP despite medication is a pattern clinicians see more often than patients expect. The most common piece of advice a heart failure patient hears is to never miss a dose. It is sound advice. But there is a limit that even a patient who never misses a dose can run into. Ruth was one of them. She took every medication on schedule, and her blood numbers still climbed.
One of the markers used to follow heart function is NT-proBNP. It rises when the heart is under pressure or strain. At an admission a few weeks earlier, Ruth’s NT-proBNP was about 2,400. When she reached the emergency room this time, it was in the 7,600 range. She had never stopped the medication, yet the number had more than tripled.
There was a second medication in the picture. Because a clot had formed inside her heart, she took the anticoagulant warfarin. She took that one every day without missing it too. Even so, the INR measured this time was 1.6, below the target range of 2.0 to 3.0. The blood was not thinned enough, despite the warfarin.
So the question in this case is not whether the patient took her medication. It is what a physician adjusts, and how, when a patient takes everything and two numbers still drift apart. How far to raise a diuretic when congestion comes back in advanced heart failure where the ejection fraction has fallen to 20 percent. Whether to switch the drug when warfarin slips below target. How to weigh an older patient’s bathroom burden against the dose she needs. These are decisions without a fixed answer.
This is not the story of every 71-year-old American woman. It is a look, in numbers, at how two risks can climb at the same time in an advanced heart failure patient who takes every medication, and at how a prescription gets reset at that point. Below are the days that brought her in.
The Medications Were the Same, but One Number Tripled
Ruth was 71 and lived in an assisted living setting. She was obese and walked with a walker. Her legs carried lymphedema. Her kidney function sat at chronic kidney disease stage 3, and she had high blood pressure and high cholesterol.
Her cardiac history was heavy. A nonischemic cardiomyopathy had left her heart’s pumping function severely reduced. Her left ventricular ejection fraction, or EF, was 20 percent. Against a normal range of 55 to 70 percent, the force pushing blood out with each beat was about a third of normal. An implantable device, an ICD, had been placed to guard against a sudden dangerous rhythm.
The previous winter, a clot had been found inside the left ventricle of her heart. When the pump is weak, blood moves slowly inside the chamber, and blood that pools in one place tends to clot. Warfarin had been started for that clot, planned for several months.
There had been one hospital stay a few weeks before. A gastrointestinal bleed was suspected. While bleeding is a concern, a diuretic can deepen dehydration, so it was held for a time. At discharge, her diuretic, Lasix, was reduced from twice a day to once a day. And Ruth found frequent trips to the bathroom hard. She had to move with a walker, and the constant urge to urinate wore on her. A bedside commode was under consideration.
After that, the swelling came back. The dose reduction and the underlying progression of the heart failure appeared to be working at the same time.
From Chest Pain to the Emergency Room
Last winter. A left ventricular clot was found. Warfarin was started.
A few weeks ago. Admitted for a suspected GI bleed. The diuretic was held for a time. At discharge, Lasix was cut from twice a day to once a day. NT-proBNP was about 2,400 at that point.
Yesterday. An outpatient blood draw came back with a rise in troponin and BNP, and she was notified.
This morning. The center of her chest hurt, a 10 out of 10. The pain eased not long after it began. Around the same time, one hand went weak and her speech slurred briefly, then returned to normal.
The call. The facility called EMS. On the way to the emergency room, she was given aspirin 324 mg before arrival.
Arrival. Ruth reached the emergency room without knowing exactly what was happening to her.
Heart Failure Rising BNP Despite Medication: What the ED Workup Found
Vitals on arrival: blood pressure 134/80, heart rate 92, respiratory rate 18, oxygen saturation 93 percent on room air, temperature 36.6 degrees C, no fever. She had mild breathlessness but denied any new chest pain at that point.
The blood results read as follows. NT-proBNP in the 7,600 range, well up from about 2,400 at the last admission. INR 1.6, below the target range of 2.0 to 3.0. Troponin was mildly elevated, and a repeat at three hours showed little change. Kidney function sat at her baseline chronic kidney disease stage 3.
Chest X-ray: an enlarged heart, with pacemaker and ICD leads visible, and low lung volumes.
On the neurological side, because the hand weakness and slurred speech had resolved quickly, head imaging was obtained. There was no large stroke, but findings suggested microembolism. The suspicion was that a small fragment had broken off the clot inside the heart, briefly blocked a vessel in the brain, then cleared. The chest pain and the mild troponin rise were read in the same frame, raising the possibility that a small fragment had traveled toward a coronary vessel as well.
The Admitting team entered the following orders. Recheck the INR immediately and reassess the anticoagulation strategy. Use an echocardiogram to re-evaluate the shape and size of the left ventricular clot and the EF. Neurology consultation. Cardiology and nephrology consultation. For the congestion, escalate the loop diuretic, since guidelines call for raising the IV dose or adding a second diuretic when congestion persists. (2022 AHA/ACC/HFSA) Supportive care with oxygen, fluid management, and treatment for pain and nausea. Admission to a floor with cardiac monitoring.
Plain-Language Reference
| Term | What It Means in Plain Language |
|---|---|
| HFrEF (reduced ejection fraction heart failure) | Heart failure in which the pump force is reduced. Each beat sends out less blood than normal. |
| EF (ejection fraction) | The share of blood the heart sends out with each beat. Normal is 55 to 70 percent. Twenty percent is severely reduced. |
| Left ventricular thrombus | A blood clot inside the heart’s main pumping chamber. It forms more easily when a weak pump lets blood move slowly. |
| Embolism | A fragment that breaks off a clot, travels through a vessel, and blocks another spot. When it reaches the brain, it causes a stroke. |
| Microembolism | A very small fragment that briefly blocks a vessel, then clears. Symptoms can resolve on their own. |
| TIA (transient ischemic attack) | A brief block of blood flow to the brain that clears, so symptoms fade quickly. It is treated as a warning sign for a larger stroke. |
| INR | A measure of how much warfarin has thinned the blood. For a clot, the usual target is 2.0 to 3.0. |
| Warfarin | A blood thinner that helps prevent clots. It reacts strongly to food and other drugs, so the INR has to be checked often. |
| NT-proBNP | A marker that rises when the heart is under pressure or strain. It goes up in heart failure. |
| ICD | An implanted defibrillator. If a dangerous rhythm starts, it delivers a shock to stop it. |
| Loop diuretic (Lasix) | A drug that pulls fluid out through the urine to reduce swelling and congestion. |
| Diuretic down-titration | Lowering the diuretic dose. When the dose drops, congestion can return. |
| Congestion | A state in which fluid builds up in the body, causing swelling and shortness of breath. |
| Clinical Marker | Patient’s Presentation | Significance & Reference Literature |
|---|---|---|
| NT-proBNP, Rising on Stable Medication | ~2,400 to ~7,600 | Each doubling of NT-proBNP was tied to a 17 percent higher risk of cardiovascular death or heart failure hospitalization, and the rise preceded the event by about 200 days on average (ACC 2023). |
| EF 20 Percent, Severe HFrEF | ~1/3 of normal output | In HFrEF, an NT-proBNP at or above 1,858 pg/mL was an independent factor for 90-day death or readmission (PLOS One 2024). |
| Diuretic Cut, Then Returning Congestion | Twice daily to once daily | After a diuretic dose was lowered, 30-day hospitalization was 3.4 percent and death 2 percent, against 1 percent and 0.6 percent on a stable dose: roughly double the hospitalization risk and triple the death risk at similar congestion (ESC Heart Failure 2025). |
| LV Thrombus on Warfarin, INR Below Target | INR 1.6 (target 2.0 to 3.0) | The estimated stroke rate with an LV thrombus is about 16 percent, and it rises with subtherapeutic anticoagulation (JACC Advances 2025). |
| Transient Hand Weakness and Slurred Speech | Resolved quickly | A possible TIA pattern. With an LV thrombus present, it can signal a small fragment that briefly blocked a brain vessel, even when imaging shows no large stroke. |
The medications were unchanged, yet one number tripled and the other sat below its target.
From the Reviewer · Eleanor Hayes, M.D.
(A) When the number rises even though every dose is taken
In cases like this, an NT-proBNP that climbs despite faithful dosing is not unusual. NT-proBNP reflects the pressure and strain on the heart, and there is a limit to how far a fixed dose can hold that down once the disease advances. An EF of 20 percent is advanced heart failure, and advanced heart failure generates higher pressures over time even on the same drugs. A rising number does not mean the medication has failed. It means that, at that moment, the force of the disease was pushing harder than the medication was holding back, which is the point at which the dose, not the patient’s adherence, is what gets reassessed.
(B) What it means when NT-proBNP rises
In one analysis, each doubling of NT-proBNP was associated with a 17 percent higher risk of cardiovascular death or heart failure hospitalization, and the rise preceded the event by about 200 days on average. (ACC 2023) In HFrEF patients, an NT-proBNP at or above 1,858 pg/mL has been reported as independently linked to death or readmission within 90 days. (PLOS One 2024) The direction of change tells you more than a single value does. A move from about 2,400 to the 7,600 range has to be read as a trend, not a snapshot.
(C) What happens when a diuretic is cut, and what is done about it
A diuretic pulls fluid out of the body and relieves congestion. Lower the dose and the fluid returns. In one study, lowering a diuretic dose was followed within 30 days by hospitalization in 3.4 percent and death in 2 percent, against 1 percent and 0.6 percent for those kept on a stable dose: roughly double the hospitalization risk and triple the death risk at similar levels of congestion. (ESC Heart Failure 2025) For this patient there was a sound reason to cut the diuretic when bleeding was suspected, but the return of congestion that followed is not separate from that decision. When congestion comes back acutely, the 2022 AHA/ACC/HFSA guideline points one way: raise the IV loop diuretic dose, or add a second diuretic, until the congestion clears. (2022 AHA/ACC/HFSA) The harder question is not the inpatient dose but the maintenance dose afterward.
(D) The bathroom burden, weighed against the dose she needs
A diuretic means frequent, urgent trips to the bathroom. For an older person with limited mobility, that is not a small matter. Having to move with a walker and get up several times a night takes a real toll on daily life, so it is understandable that a patient wants to cut back. In the hospital, with acute congestion, the dose goes up because that is what clears the fluid. The difficulty sits in the maintenance dose set at discharge, where the choice is not two-way. A recent suspected bleed argues for caution. Congestion that returned on the lower dose argues for more. The bathroom burden, a quality-of-life concern, argues for less. Setting that long-term dose means balancing all three at once, which is why it belongs to the patient and the care team together rather than to any one rule.
(E) Why a clot forms in the left ventricle
When the pump is weak, blood moves slowly inside the heart, and blood that lingers in one place clots more easily. That a lower EF carries a higher risk of left ventricular thrombus has been known for a long time. LV thrombus rates as high as 19.2 percent have been reported in patients with an EF below 50 percent. (JACC Advances 2025) An anticoagulant in a patient with an EF of 20 percent is meant to keep that clot from growing or breaking loose.
(F) An INR below target even though the drug was taken
Warfarin responds heavily to food, to other drugs, and to day-to-day changes. Even on the same daily dose, the INR can drift outside the target. This patient’s INR of 1.6 was below the target of 2.0 to 3.0. The estimated stroke risk with a left ventricular thrombus is about 16 percent, and it rises when anticoagulation is below target. (JACC Advances 2025) In other words, even with the drug on board, if the blood was not thinned enough at that moment, a window opened for a fragment to break away.
(G) Why a brief neurological symptom is hard to wave off
One hand going weak and speech slurring, then returning to normal, can be a TIA, a transient ischemic attack. The symptom fading does not mean it is over. In a patient with a left ventricular thrombus, it can be the signal of a small fragment that briefly blocked a brain vessel and then cleared. When imaging shows no large stroke but suggests microembolism, that is how it is read. The chest pain and the mild troponin rise are held in the same frame, raising the chance that a similar fragment traveled toward a coronary vessel.
(H) The context of a mildly elevated troponin
Patients with a low EF often run a chronically slightly elevated troponin. So a single mildly raised value does not, on its own, say heart attack. But in a 71-year-old with chest pain, a left ventricular thrombus, and an INR below target, that mild rise raises a question worth asking: demand-supply mismatch, or a small embolism. The context, not the absolute value, sets the meaning.
(I) How to reset the anticoagulation, and the bleed that sits in the way
The American Heart Association’s 2022 statement on left ventricular thrombus lays out several directions. When the INR is repeatedly below target on warfarin, switching to a different anticoagulant, a DOAC, is reasonable to consider. When a clot persists despite a therapeutic INR, low molecular weight heparin is considered. A protruding or mobile clot carries a higher embolic risk. (AHA Circulation 2022) In practice there is a case of a patient who kept having emboli despite anticoagulation and was moved, after a multidisciplinary review, to warfarin with low molecular weight heparin bridging, which stabilized the INR with no further emboli. (Cureus 2025) The hard part here is that the two risks point in opposite directions. Pushing the anticoagulation harder guards against another embolism, but in a patient who was just admitted for a suspected bleed, it raises the risk of bleeding again. Where to set the INR stops being a simple adjustment and becomes a judgment between the two.
(J) The picture so far
This is not a stage that calls for a biopsy or for more testing. But put this patient’s numbers together and they point one way. An EF of 20 percent in advanced heart failure, an NT-proBNP that rose from about 2,400 to the 7,600 range, congestion that returned after the dose was cut, an INR below target, and a neurological symptom that cleared quickly. No single one of these is decisive, but set side by side they form a picture in which two risks were climbing at once even though every medication was taken.
(K) What Bends the Curve
A handful of decisions open up for this patient over a short span, and the difficulty is that they pull against one another. Pressing on one tends to lift another.
- Reset the anticoagulation. Find out why the INR was below target, then decide among a warfarin dose change, low molecular weight heparin bridging, or a switch to a DOAC, while weighing the recent suspected bleed.
- Re-image the clot. Look again at the clot’s shape, size, and movement to gauge embolic risk, and recheck the EF.
- Set the maintenance diuretic dose. The acute congestion calls for raising the dose now; the longer-term dose has to sit between bleeding risk and congestion, with the bathroom burden as a quality-of-life factor held in the same view.
- Track the neurological symptoms. Watch for the TIA pattern returning, and involve neurology if it does.
- Optimize the heart failure medications. Fit as much guideline therapy as an EF of 20 percent calls for, within what the kidneys and the blood pressure will allow.
The answers to these belong to the patient and the cardiology, neurology, and nephrology teams. Tighten the anticoagulation and the bleeding risk climbs; lean on the diuretic and the bathroom burden and the kidneys push back; add a heart failure drug and the blood pressure may not allow it. The point is not a single correct move but a balance, and the figures laid out above are only the distribution before that balance is struck.
Two Costs, One Decision Window
| Clinical & Behavioral Scenarios | Estimated Facility Billing | Patient Out-of-Pocket (PPO) |
|---|---|---|
| (1) Decompensated heart failure admission with monitoring (4 to 6 days) | $25,000 to $55,000 | ~$8,500 (annual OOP max hit) |
| (2) Ongoing: anticoagulation monitoring, repeat echo, clinic follow-up (per year) | $2,000 to $6,000 | Low (routine management) |
| (3) Add: embolic complication (stroke or coronary event) workup and care | +$60,000 to $200,000 | Annual OOP max re-hit |
| (4) Multi-year course: repeated admissions, device care, imaging, and supportive care | +$200,000 to $500,000 | Annual OOP max + caregiving-cost risk |
Sources: AHA Circulation 2022 (LV thrombus statement); ESC Heart Failure 2025 (diuretic down-titration); JACC Advances 2025 (LV thrombus stroke risk). Facility and out-of-pocket figures are scenario estimates for a typical PPO and vary by plan and region.
Here is the core of it. Advanced heart failure with an EF of 20 percent can be slowed by medication but is hard to reverse. NT-proBNP can rise even when every dose is taken, and the INR can drift below target even on daily warfarin. So care at this stage is less about adding a drug than about resetting the ones already in use: how much diuretic, which anticoagulant, at what interval to check. For Ruth, the larger problem was not cost but whether there was someone close enough to look often at how far each of the two drugs was still working.
The same pattern of medication reaching its limit in heart failure runs through the case of a patient who stopped a blood pressure medication and went into heart failure. The way a serious finding can surface while a workup is aimed elsewhere appears in the case of a month of back pain that turned out to be multiple myeloma. How a patient without a regular primary care physician is affected at a decisive moment is laid out in the case of older men living alone who arrive in the emergency room.
Tools for Reading Longevity and Heart Numbers
A single result rarely tells the whole story. Three calculators that help frame longevity, cardiac, and blood-panel numbers against age-matched references.
· Life Calculator (Longevity Estimate)
· Heart Age Calculator (Cardiovascular Age Estimate)
· Blood Work Decoder (Cardiac & Metabolic Panel Reader)
Ruth was admitted to a monitored floor for anticoagulation reassessment and diuretic adjustment. The emergency room settled one thing. It accounted for why two numbers had drifted apart while she took every medication on schedule. The cause was not a missed dose. It was the limit of what those medications could hold at an EF of 20 percent, and an INR that had slipped below its target.
An echocardiogram was scheduled to re-evaluate the clot and the EF, with the anticoagulation strategy to be reset depending on the result. The diuretic dose, the choice of anticoagulant, and the follow-up interval are the agenda during the hospitalization. Which combination fits this patient is decided after those results, among the cardiology and nephrology teams and the patient herself.
This article is for general information and does not provide medical advice. The case described is a composite reconstructed from publicly reported clinical patterns and does not represent any specific patient. New chest pain, sudden weakness or slurred speech, worsening swelling or breathlessness, and questions about anticoagulation or diuretic doses can be raised with a physician or through an emergency room visit. Prescribed medications, especially blood thinners and diuretics, should never be stopped or adjusted on your own.
Take care of yourself. Nobody else will do it for you.
Wilbur P is the editor of Manclub, leading coverage across health and life. His work is research-driven and built on primary sources a reader can verify – written for men in the second half of life who would rather know than believe. Based in Florida, still learning and still in the fight. Corrections, questions, story tips: [email protected].